PGNY Stock Recent News

'Mad Money' host Jim Cramer shares his small-cap healthcare stock picks.

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 1:30 P.M. Eastern Time.

Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.

Progyny, Inc. (PGNY) is recommended as a buy due to its potential for continued growth and positive long-term outlook. The recent weak share price is attributed to expected weak performance in 1Q24, but this is believed to be a temporary issue. PGNY's active pipeline is the largest it has ever been, indicating future growth opportunities, particularly in the women's health vertical.

NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Michael Sturmer, Progyny's President, will participate in a fireside chat at Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024 at 10:15 A.M. Eastern Time.

Progyny's stock is trailing the S&P 500 thus far in 2024 amongst macro concerns such as the Alabama court ruling on frozen embryos. However, Progyny's Q4 2023 revenue grew by 26%, and the company continues to add clients and increase the number of covered lives. With no debt and ample cash, the company authorized a share repurchase program up to $100 million.

Shares of fertility-solutions firm Progyny are in the red on disappointing guidance. The company says the Alabama court ruling on in vitro fertilization won't affect it.

Progyny, Inc. (PGNY) Q4 2023 Earnings Call Transcript

One of the fun things about writing about stocks for a living is the library of content you can draw upon for inspiration. Back in June 2020, we were deep in the pandemic, so I wrote a piece about cash-rich stocks to buy for peace of mind.

Progyny, Inc. demonstrates strong resilience and sustained growth potential in a weak macro backdrop. The company's revenue grew 37% year-over-year, beating estimates, with strong performance in fertility benefit services and pharmacy revenue. The contract with the federal government presents a major growth opportunity and the potential for upselling.